Hepatitis

23% achieved HBsAg loss with xalnesiran plus immunomodulator, but relapses occurred in some

Also in TTHealthWatch: HIV-positive kidney donors

Fatty acid synthase inhibitor targets main drivers of liver injury

These high reinfection rates indicate treatment has reached highest-risk population

Study in line with prior evidence implicating mother's preconception HBV infection

An anesthesiologist may not have followed infection control practices

Hospital setting may offer unique opportunity to increase vaccination rates

Results as quick as 1 hour, enabling a test-and-treat approach

Androgen precursor may help cirrhosis-related sarcopenia

"Is it time to say primary prophylaxis is dead?" one expert asks

GLP-1/GIP agonist also improved fibrosis biomarkers, liver fat, and stiffness in phase II trial

iLFT is now an essential, highly utilized tool at one U.K. primary care system

Combo therapies for HDV with drugs other than pegylated interferon would be better, expert says

94% of people completed primary vaccination in this Baltimore-based initiative